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Konsensbasierte Leitlinie der Deutschsprachigen Medizinischen
Gesellschaft für Paraplegiologie zur Behandlung von Schmerzen bei
Querschnittlähmung
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Introduction: Pain is a prominent complication in spinal cord injury (SCI).
It can either occur as a direct or as an indirect consequence of SCI and
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Introduction
Acute and chronic pain are crucial complications in the
course of spinal cord injury (SCI), entailing serious impacts
not only on the primary rehabilitation, but also on the in-
dividuals’ quality of life in later phases of SCI [1], [2], [3].
The vast majority of individuals with SCI experiences pain
of any manifestation at some time after injury [4], [5].
Most frequently, pain occurs within the early phase of
disease but also commonly emerges in later stages, for
instance, as consequence of complications in direct or
indirect relation to SCI [4], [6]. Hence, numerous varieties
of pain presentation are common in SCI. These presenta-
tions can generally be assigned to different pain types,
some of which are very common, like nociceptive and/or
neuropathic pain. Such pain types can be present at
and/or below the neurological level of injury (NLI), but
also in body regions that are not affected by SCI.
Nociceptive pain is defined as pain that is caused by
either an irritation or an injury of body tissue, without an
associated impairment of somatosensory structures [7].
This type of pain can be addressed by means of a causal
treatment but could also evolve into a chronic condition.
Three subtypes are common in SCI: 1) musculoskeletal,
2) visceral, and 3) other nociceptive pain. While musculo-
skeletal pain in SCI is mostly due to mechanical damage
with ensuing injury of bones (fractures), muscles, liga-
ments and joints [8], visceral pain is frequently resulting
from constipation. Other nociceptive pain could be caused
by pressure sores.
According to the International Association for the Study
of Pain, neuropathic pain is defined as “pain arising as
a direct consequence of a lesion or disease affecting the
somatosensory system” [9]. ‘Definite neuropathic pain’
can be diagnosed if medical history suggests a disease
that could potentially lead to a lesion of the somato-
sensory system, and if the pain is distributed in a neuro-
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Figure 1: Adapted grading system for neuropathic pain after spinal cord injury (SCI) according to the International
Association for the Study of Pain (IASP) [12]
anatomically plausible pattern (e.g. according to a derma-
tome or a cutaneous innervation), and if the former,
as well as the latter condition is confirmed by clinical or
instrument-based (e.g. MRI) examinations [10]. This al-
gorithm has recently been adapted for application in SCI
(Figure 1) [11], [12]. Neuropathic pain in general is further
subdivided into central and peripheral neuropathic pain.
While the latter is due to a lesion of peripheral neural
structures (e.g. peripheral nerves or nerve roots), the
former is related to an impairment of the central nervous
system, like certain structures within the spinal cord (e.g.
sensory neurons in the grey matter or afferent white
matter tracts) [13]. Peripheral neuropathic pain frequently
presents as, but is not limited to, evoked pain (e.g. tactile
stimuli), whereas central neuropathic pain is character-
ized by spontaneous and continuous pain presentation
[14], [15]. At-level neuropathic pain in SCI is localized at
and/or within three levels below the NLI and can be
caused by both lesions of the peripheral nervous system
(e.g. nerve roots) and lesions of the spinal cord itself. In
contrast, neuropathic pain which is localized more than
three segments below the NLI is commonly considered
as central and defined as below-level neuropathic pain
[16]. Notably, pain in SCI can also be triggered by noci-
ceptive stimuli below the NLI, which frequently cannot be
perceived by the patient (e.g. bladder infection). Thus,
classification and grading of pain can be quite challen-
ging, particularly if causes of pain are located below the
NLI [17].
Except for some evidence reporting that cervical lesions
might be related to a higher probability to develop central
neuropathic pain, no further predisposing factors are
known, yet. Neither the severity of SCI, nor the NLI are
proven to have influence on the emergence of distinct
pain types or the intensity of perceived pain [18].
Concerning the efficient treatment of SCI-related pain,
there are two meta-analyses on pharmacotherapy in
general and one on gabapentinoids in particular, one on
a surgical intervention (DREZ lesion) and one on physical
or behavioral treatment [19], [20], [21], [22], [23]. Over-
all, however, evidence is still sparse and therapeutic op-
tions are limited, especially with regard to neuropathic
pain. According to current understandings, optimized
management of pain in SCI is dependent on a well-
matched personalized approach, which involves both
pharmacological and non-pharmacological means [3].
All these evident specifics and challenges emphasize the
need of a systematic and structured approach for pain
management in SCI, such as clinical practice guidelines.
Accordingly, the primary goal of this clinical practice
guideline is to establish and standardize a broadly ap-
proved and recognized concept to address the frequent
challenges regarding themanagement of SCI-related pain
syndromes in German-speaking countries. This in turn
will likely improve health care in affected SCI individuals
and represents a basis to develop more effective thera-
peutic options in the future.
This guideline addresses physicians and therapists of all
participating medical societies and specialist disciplines
(e.g. neurologists, physiatrists, pain specialists, orthope-
dists, psychotherapists). It should serve as a source of
information for all further professional fields that are in-
volved in the treatment of adult individuals with acute
and chronic spinal cord injury in out- and inpatient setting.
Methods
This consensus-based clinical practice guideline was de-
veloped by the German-Speaking Medical Society for
Spinal Cord Injury (DeutschsprachigeMedizinischeGesell-
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Table 1: Review process within the clinical practice guideline panel
Table 2: Guidance for the appraisal of recommendations
Table 3: Grading of recommendations
schaft für Paraplegiologie, DMGP) in accordance with the
applicable regulations of the Association of Scientific
Medical Societies in Germany (Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften
e.V., AWMF) and the methodological requirements of the
German instrument formethodological guideline appraisal
(DELBI) [24], [25]. According to the three-stage concept
of the AWMF it is a S2k guideline. The AWMF is represen-
ting Germany in the Council for International Organiza-
tions of Medical Sciences (CIOMS; https://cioms.ch).
Methodological accuracy
An evidence base derived from Pubmed®, Medline®, and
the Cochrane Library, as well as statements from preced-
ing international guidelines were subjected to a structured
consensus-building process [26], [27], [28]. Statements
with regard to taxonomy, classification, and diagnostic
procedures are based on widely accepted algorithms and
tools that had already been evaluated, rated, and en-
dorsed by international societies like the International
Spinal Cord Society (ISCoS), the American Spinal Injury
Association (ASIA), or the International Association for
the Study of Pain (IASP) [10], [11], [29], [30], [31]. Accord-
ingly, non-controversial statements were evaluated within
the regular review process of the guideline content
(background text) without a formal voting procedure
(1st through 4th revision within the guideline panel; see
Table 1). All representatives of the guideline panel had
the opportunity to comment on each statement and the
full content of the background text by use of a form
throughout the review process.
In contrast, relevant pharmacological and non-pharmaco-
logical therapeutic approaches are frequently based on
sparse or even conflicting evidence. In particular, phar-
macological interventions are tightly regulated by author-
ities varying from country to country. Thus, potential
therapeutic options were rated by means of a structured
voting procedure (3rd and 4th revision within the guideline
panel). The evaluation of existing evidence was oriented
towards the GRADE process (Grading of Recommenda-
tions Assessment, Development and Evaluation) [32],
[33]. Correspondingly, the pre-defined specifications to
appraise the strength of recommendations are listed in
Table 2. Considering the limited standardization of liter-
ature review, the quality of identified evidence was not
explicitly rated and expressed with descriptions like
“high”, “moderate”, or “(very) low” as it is exemplarily
specified according to GRADE. Nevertheless, the analysis
of existing evidence influenced the wording of stated re-
commendations for pharmacological and non-pharmaco-
logical therapies, which were graded on a three-level scale
according to Table 3. The strength of consensus was
4/26GMS German Medical Science 2019, Vol. 17, ISSN 1612-3174
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Table 4: Rating of reached consent
Table 5: Members of the steering committee
Table 6: Listing of participating societies/organizations and their representatives
finally determined by the approval rating for each recom-
mendation (Table 4).
After completion of the consensus within the panel, the
guideline was submitted to the AWMF for a final external
review (methodological monitoring), to the board of the
DMGP guideline commission, as well as to all authorized
bodies of the involved associations and societies for a
concluding content review.
Constitution and structure of the
guideline panel
Commissioned by the DMGP, the corresponding author
convened a representative committee and coordinated
the structured consensus building of the guideline project.
The guideline panel was subdivided into a steering com-
mittee (Table 5), constituted of experts from different
disciplines – neurologists, psychologists, pain specialists,
a physiatrist, and a physiologist – who are involved in the
diagnosis and treatment of SCI, and a group of appointed
representatives from seven German-speaking scientific
medical societies and one patient organization (Table 6).
Process of structured consensus building
During a project kick-off meeting the steering committee
decided on outline and main content of the planned
guideline. Subsequently, each member of the steering
committee was assigned to a work group charged with a
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Table 7: International Spinal Cord Injury Pain (ISCIP) Classification [30], [31]
specific topic of the guideline and commissioned to pre-
pare a topic-related draft. Thereafter, the drafts were
combined to a first preliminary version of the guideline,
which again went through a review process, firstly within
the steering committee.Within this process, all committee
members were required to screen existing evidence/liter-
ature, available international guidelines and relevant re-
commendations of international societies. In addition,
committee members contributed their own reasoned ex-
pert opinion.
The structured process of consensus building within the
whole guideline panel was initiated after the conclusion
of the steering committees’ review process. Representa-
tives of each aforementioned society/association and
members of the steering committee were asked to com-
ment and edit the guideline as appropriate (1st and 2nd
revision within the guideline panel). In each of the two
rounds, the steering committee prepared a revised ver-
sion of the guideline for re-submission to the group.
Subsequently, the coordinator of the consensus-building
process analyzed the preliminary guideline in terms of
core statements and grading of recommendations. The
core statements and recommendations were then sum-
marized to be voted upon (3rd and 4th revision within the
guideline panel). All members of the guideline panel were
required to judge about every single item. In case of dis-
sent, each member had to either justify the decision or
to provide alternative suggestions. Whenever possible,
a dissent needed to be supported by relevant published
evidence. Suggestions were submitted to the guideline
panel along with a commented revised draft of the
guideline, which was previously prepared by the steering
committee. All members were asked to decide about the
revised proposals and to comment on the suggestions of
the steering committee if necessary. This procedure was
iterated until a unanimous consent was achieved.
Throughout the process of guideline development, all
group members were called upon to check for recently
published or by then missed literature and evidence, re-
spectively. Furthermore, throughout the guideline devel-
opment emerging expert statements in the context of
pain treatment could be incorporated if relevant. A sum-
mary of the structured consensus building is given in
Table 1. In a concluding survey among all members of
the panel, the guideline was finally consented and ap-
proved by the participating societies.
Results
The structured consensus process led to a clinical prac-
tice guideline of S2k classification according to the AWMF
guidance manual and rules [24] and resulted in the fol-
lowing statements and recommendations arranged ac-
cording to different groups of themes:
Classification of SCI-related pain
• Statement 1.1
The classification of SCI-related pain ought to be done
according to the international spinal cord injury pain
(ISCIP) classification (Table 7) [30], [31].
Diagnosis of SCI-related pain
General considerations regarding diagnostic
routines
• Statement 2.1
Diagnosis of SCI-related pain ought to be done in a
structured and standardized manner. Therefore, it
should be based on the recently published and widely
accepted International Spinal Cord Injury Pain Datasets
(ISCIPD) [34], [35].
• Statement 2.2
In case psychological factors influence pain perception,
this ought to be considered as “chronic pain disorder
with somatic and psychological factors” according to
the international statistical classification of diseases
and related health problems (ICD-10), published by
the World Health Organization (WHO) [36].
• Statement 2.3
Yet, the ISCIPD is not translated and linguistically val-
idated in German. Thus, the German pain question-
naire (Deutscher Schmerzfragebogen, DSF)may serve
as a basis with respect to the patient medical history
and screening for psychological comorbidities [37].
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Basic notes on the clinical examination as part
of diagnostic routines
• Statement 3.1
Nociceptive pain ought to be examined by
means of an accurate past medical history re-
1.
cord and a clinical examination of all body re-
gions that are potentially exposed to substantial
physical exertion in the wake of SCI.
2. Visceral pain is most commonly due to compli-
cations regarding neurogenic bladder and bowel
dysfunction.
• Statement 3.2
SCI-related neuropathic pain should be clinically eval-
uated as follows (Figure 1) [38]:
Onset of pain within the first year of injury?•
No competing causes of pain (e.g. scars, skin
wounds, ulcers)?
•
Presentation of pain has no dependency on move-
ment/manipulation of the painful area?
•
One or more of the following pain qualities:
“hot/burning”, “tingling”, “electrical“, “constricting/
squeezing” or “freezing”?
•
Is the painful area located in a body region of abnor-
mal sensory function (hypesthesia, allodynia, hyper-
algesia)?
•
• Statement 3.3
Supplementary to the clinical examination, various
questionnaires and scales are available to evaluate
pain [39], [40], [41], [42].
Basic notes on the medical diagnostics
• Statement 4.1
Depending on the cause, assessment of nociceptive
pain can be supported by several diagnosticmeasures.
Most commonly, imaging (sonography, X-ray diagnos-
tics, computed tomography [CT], magnetic resonance
imaging [MRI]) is the preferred approach to further
evaluate the causes of nociceptive pain with respect
to its underlying structural changes.
• Statement 4.2
For affirming the diagnosis of SCI-related neuropathic
pain, imaging techniques are preferably used to detect
a spinal cord lesion (CT, MRI). Furthermore, neuro-
physiological measures can help to evaluate the integ-
rity of relevant spinal tracts. Well established tech-
niques include somatosensory evoked potentials
(SSEP) for examining lemniscal functions, contact heat
evoked potentials (CHEPS) and laser evoked potentials
(LEP) for testing nociceptive and thermoreceptive tracts
and motor evoked potentials (MEP) for assessing the
corticospinal tract [43], [44], [45], [46], [47], [48],
[49], [50].
• Statement 4.3
The Quantitative Sensory Testing (QST) may be con-
sidered in case of uncertainty concerning the interpre-
tation of symptoms with respect to neuropathic pain
[51], [52], [53], [54].
Prediction and prevention of pain in SCI
• Statement 5.1
Conclusive evidence to prevent and predict pain after
SCI is missing [55].
• Statement 5.2
Potential risk factors for pain chronification, such as
age or an early onset of pain, are being subject to on-
going discussions.
However, it is generally accepted that the avoidance
of secondary complications after SCI is of utmost im-
portance to diminish the risk of nociceptive pain devel-
opment and its chronification [56], [57].
• Statement 5.3
Early presentation of allodynia in certain skin areas
might be a predictor of developing neuropathic pain
[54].
Considerations regarding treatment of
SCI-related pain
Expectations on treatment
• Statement 6.1
Therapeutic goal setting ought to be reasonable and
realistic. Complete pain relief is unlikely to occur.
Current level of evidence
• Statement 6.2
As a basis for designated treatment recommendations,
five meta-analyses exist, especially concerning phar-
macological therapeutic approaches.
However, existing evidence on treatment of SCI-related
pain is sparse, and further research in terms of ran-
domized controlled trials (RCT) is required [19], [20],
[21], [22], [23].
General considerations
• Statement 6.3
A timely and sufficient treatment of pain, irrespective
of the pain type and based on current pathophysiolo-
gical insights, is of utmost importance [58].
• Statement 6.4
The primary therapeutic objective is to treat underlying
injuries, causes and triggers.
Specific considerations in relation to
nociceptive pain
• Statement 6.5
TheWHO’s analgesic ladder including adjuvants serves
as basic guidance for treatment of nociceptive pain
[59].
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Table 8: Substance-related undesirable side effects in treatment of neuropathic pain of particular relevance for SCI
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• Statement 6.6
Indications and side effects of analgesics have to be
evaluated in respect to their particular relevance in
SCI (Table 8).
• Statement 6.7
Based on broad clinical expert experience, nonsteroidal
anti-inflammatory drugs (NSAR) are considered to be
effective in acute nociceptive pain.
• Statement 6.8
The adequate supply of medical aids plays a central
role with respect to the treatment of nociceptive pain
[60].
Specific considerations in relation to
neuropathic pain
• Statement 6.9
Treatment of neuropathic pain is primarily a symptom-
atic therapy, unless underlying causes can be ad-
dressed [61].
• Statement 6.10
Adjuvants, which are in accordance with the WHO’s
analgesic ladder are considered to be equivalent to
the drugs that also have a therapeutic effect on
neuropathic pain.
• Statement 6.11
There is a lack of evidence regarding efficacy of NSAR
in neuropathic pain relief.
Pharmacological options for treatment
of SCI-related pain
Anticonvulsants
RECOMMENDATION 1.1: PREGABALIN
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↑↑
Strength of consent: strong
DOSAGE AND ADMINISTRATION
Approved daily maximum dose:
600 mg in 2 or 3 single doses
Dose increase:
weekly, starting with 150 mg p.d. (per day)
BASIC INFORMATION AND BODY OF EVIDENCE
Pregabalin is recommended to be applied as first-line
therapy. This is based on onemeta-analysis and four RCT,
showing a positive effect on pain relief, occasionally in
lower doses, but most commonly in doses of =300 mg
[23], [62], [63], [64], [65].
RECOMMENDATION 1.2: GABAPENTIN
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↑↑
Strength of consent: strong
DOSAGE AND ADMINISTRATION
Approved daily maximum dose:
3600 mg in 3 single doses
1st day: 100 mg t.i.d. (three times a day)
2nd day: 200 mg t.i.d.
3rd day: 300 mg t.i.d.
From then on: increase by 300 mg p.d., every other day
BASIC INFORMATION AND BODY OF EVIDENCE
Gabapentin is recommended to be applied as first-line
therapy, if and when undesirable side effects occur or
efficiency is unsatisfactory with pregabalin. Use of
gabapentin is off-label for central neuropathic pain (below-
level), however approved for peripheral neuropathic pain
(at-level) in Germany. Tolerability of its application has to
bemonitored continuously. After one week of administra-
tion, 1800 mg p.d. should not be exceeded; 2400 mg
p.d. should be reached earliest after two weeks; and
3600 mg should not be given before three weeks after
the first administration. This is based on one meta-
analysis and two RCT [23], [66], [67]. Another RCT could
not demonstrate a significant therapeutic effect of
gabapentin [68], while 3 small non-randomized studies
also suggest a beneficial effect of gabapentin on SCI-
related neuropathic pain.
RECOMMENDATION 1.3: LAMOTRIGINE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↓/in complete lesions
↔/only in incomplete lesions
Strength of consent: strong
DOSAGE AND ADMINISTRATION
Trialed daily maximum dose:
400 mg in 1 or 2 single doses
1st two weeks: 25 mg q.d. (once a day)
2nd two weeks: 50 mg q.d.
2nd month: 100 mg q.d. or 50 mg twice a day
Thereafter: in weekly intervals increase by 100 mg
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BASIC INFORMATION AND BODY OF EVIDENCE
Lamotrigine is not suggested to be applied in complete
SCI and may be considered as reserve drug (third-line) in
incomplete SCI. In one RCT (n=22) a subgroup analysis
implied an effect on perception of pain intensity in incom-
plete SCI (n=12), with however limited statistical certainty
[69], [70]. The known profile of possible side effects
(Stevens-Johnson syndrome, dizziness, somnolence, etc.)
has to be considered.
RECOMMENDATION 1.4: OTHER ANTICONVULSANTS
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↓↓
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
According to the literature available, neither sodium val-
proate [71], [72] nor levetiracetam [73], [74] are recom-
mended to be used in SCI-related neuropathic pain.
Antidepressants
RECOMMENDATION 2.1: DULOXETINE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↑/in case of additional depression and/or at-level
neuropathic pain
Strength of consent: strong
DOSAGE AND ADMINISTRATION
60 mg or 120 mg q.d.
BASIC INFORMATION AND BODY OF EVIDENCE
One RCT suggests a possible beneficial effect in SCI-
related neuropathic pain as measured by VAS (p=0,05)
[75]. Some evidence additionally proposes an effect on
peripheral neuropathic pain in other underlying diseases
[76]. Thus, duloxetine is suggested as alternative thera-
peutic option in case of additionally diagnosed depression
and/or at-level neuropathic pain, and if patient-related
conditions or other reasons discourage the use of anti-
convulsants (e.g. emerging side effects). Duloxetine
should be preferred over the tricyclic amitriptyline due to
a more favorable profile of side effects [77], [78].
RECOMMENDATION 2.2: AMITRIPTYLINE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↑/in case of additional depression
Strength of consent: strong
DOSAGE AND ADMINISTRATION
150 mg q.d.
BASIC INFORMATION AND BODY OF EVIDENCE
In one meta-analysis, amitriptyline is questioned as ap-
propriate therapeutic agent in SCI-related neuropathic
pain [22]. Two RCTs that investigated the efficiency of
amitriptyline in SCI neuropathic pain yielded conflicting
evidence [68], [79]. Accordingly, we suggest amitriptyline
only if anticonvulsants and duloxetine do not show the
desired effect and a diagnosis of depression is coincident.
Notably, the authors emphasize the frequent occurrence
of side effects of amitriptyline [22].
RECOMMENDATION 2.3: VENLAFAXINE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics:
↔/in case of additional depression
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↓↓/in case of below-level neuopathic pain
↔/in case of at-level neuropathic pain
Strength of consent: strong
DOSAGE AND ADMINISTRATION
Trialed daily maximum dose: 300 mg in 1 single dose
Initially: 37.5 mg q.d.
From then on flexible increase depending on efficacy:
1st week:max. up to 75 mg q.d.
2nd week:max. up to 150 mg q.d.
until week 6:max. up to 225 mg q.d.
weeks 8 to 10:max. up to 300 mg q.d
BASIC INFORMATION AND BODY OF EVIDENCE
One RCT (n=123) tested the efficacy of venlafaxine on
concomitant depression in individuals with SCI (primary
endpoint) [80], along with its influence on both noci-
ceptive and neuropathic pain as secondary endpoints.
The minimal effective dose resulted in 150 mg per day.
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The authors discuss an efficacy of venlafaxine exclusively
for nociceptive pain alone and in case of a mixed
nociceptive and neuropathic pain syndrome, as assumed
in case of an inconclusive result in SCIPI. Venlafaxine
may be considered in cases of nociceptive and at-level
neuropathic pain with concomitant depression. Venlafax-
ine is not recommended to be used in below-level neuro-
pathic pain alone.
Opioids
• Statement 7
Evidence concerning the administration of opioids for
mild, moderate or severe pain in SCI is generally sparse
and heterogeneous. Based on that and reflecting the
relevant profile of potential adverse drug reactions,
especially in SCI, opioids are only recommended to be
applied as last resort [81], [82], [83], [84], [85].
RECOMMENDATION 3.1: TRAMADOL
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics:
↔/necessity of risk-benefit analysis
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↔/necessity of risk-benefit analysis
Strength of consent: strong
DOSAGE AND ADMINISTRATION
Trialed daily maximum dose: 100 mg q.i.d.
Initially: 50 mg q.d.
From then on: flexible increase depending on efficacy
BASIC INFORMATION AND BODY OF EVIDENCE
One RCT (n=35) demonstrated a positive effect on the
perception of pain intensity in neuropathic pain after SCI,
however lacked precision regarding its statistical conclu-
siveness [86]. Remarkably, 47.8% of participants (11 out
of 23) within the verum group terminated the application
of tramadol, which was mostly due to adverse events.
In a recent meta-analysis investigating the effects of
tramadol in neuropathic pain relief (including SCI-related
neuropathic pain), the authors come to a precarious
conclusion, given the low quality of existing studies [87].
RECOMMENDATION 3.2: OXYCODONE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics:
↔/necessity of risk-benefit analysis
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↔/as add-on to anticonvulsants
↓/as monotherapy
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
One observational study (n=54) reports amelioration of
neuropathic pain intensity within a 3 months period of
administration after concomitant application of anticon-
vulsants and oxycodone [88]. Based on the poor evidence
and the less favorable profile of potential side effects,
oxycodone may be considered in neuropathic pain treat-
ment only as add-on therapy to anticonvulsants, weighing
the risk-benefit ratio. It may be considered as last resort
for SCI-related nociceptive pain. For lack of evidence,
oxycodone is not suggested as monotherapy for SCI-
related neuropathic pain.
Further pharmacological options for treatment
of SCI-related pain
Spasmolytic drugs
RECOMMENDATION 4.1: BOTULINUM TOXIN
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics:
↔/intramuscular injection
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics:
↓/intramuscular injection
↔/in case of below-level neuropathic pain (subcu-
taneously)
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
A case series of 28 patients reported a therapeutic effect
of botulinum toxin A (BOTOX®/Allergan) on both focal
spasticity and pain [89]. The standard doses ranged
between 10 and 118 units per muscle. The exact pain
type was not specified in this study, though. The focus of
botulinum toxin injections was on muscles remarkably
affected by clinical signs of spasticity, suggesting that
musculoskeletal pain was primarily addressed.
Referring to their own preliminary single-case study, a
workgroup fromKorea conducted a subsequent RCT with
40 included patients, discussing a positive therapeutic
effect of subcutaneously injected botulinum toxin within
the area of below-level neuropathic pain (200 units ap-
portioned to 40 injection sites in one single area of pain,
maximally representing 20% of the body surface area)
[90], [91]. However, in the same study this effect could
not be demonstrated for at-level neuropathic pain (n=9).
More importantly, the authors already critically discuss
the short period of observation (8 weeks post-injection)
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and an indeed significant, however relatively low efficacy
of botulinum toxin.
Accordingly, intramuscularly injected botulinum toxin A
may be considered for therapy of nociceptive pain, if as-
sociated with spasticity. Pending further evidence, subcu-
taneous injection of botulinum toxin may not yet be con-
sidered as a therapeutic option for neuropathic pain. A
principle recommendation against the application of
botulinum toxin A in SCI-related pain is not being pro-
nounced, considering the conceivable interactions
between spasticity, nociceptive pain, and neuropathic
pain [92], [93].
RECOMMENDATION 4.2: BACLOFEN
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics:
↑/when associated with spasticity
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↓
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Three case series and one single RCT with only a small
sample size describe a therapeutic effect of intrathecally
administered baclofen on both spasticity and SCI-related
nociceptive pain. Concerning the efficacy of baclofen on
neuropathic pain, existing evidence is still conflicting [94],
[95], [96], [97], [98], [99].
To date, orally administered baclofen has not been sys-
tematically evaluated in respect to SCI-related pain. In
summary, we suggest an oral application of baclofen only
in cases of nociceptive pain associated with spasticity.
Topical medication
RECOMMENDATION 5: LIDOCAINE AND CAPSAICIN
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔/in
case of at-level neuropathic pain
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
To date, no studies exist that investigated the efficacy of
lidocaine-medicated or capsaicin-medicated plaster and
capsaicin cream in SCI-related neuropathic pain. In the
light of an existing clinical practice guideline for treatment
of chronic neuropathic pain [100], a therapeutic attempt
may be considered if localized at-level neuropathic pain
is resistant to other therapies or in case of intolerance
towards other therapeutic options.
RECOMMENDATION 6: AGENTS FOR INVASIVE USE (IN-
TRAVENOUSLY/INTRATHECALLY)
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↓
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↓
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Evidence for the use of intravenously or intrathecally ad-
ministered agents is generally scarce. Opioids (morphine
and alfentanil), lidocaine, ketamine and clonidine have
been tested [101], [102], [103], [104], [105], [106]. All
of these studies however lack long-term investigations.
Further shortcomings comprise considerablemethodolog-
ical flaws and limitations, like small sample sizes and
conflicting results in various studies. Thus, we do not
suggest these agents for the use in both nociceptive pain
and neuropathic pain, especially when reflecting the risk-
benefit ratio of such invasive approaches.
RECOMMENDATION 7: CANNABINOIDS
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↓
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↓
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Efficacy of cannabinoids in pain related to SCI has been
evaluated in one meta-analysis which analyzed two
studies [22]. One study investigated the effect of tetra-
hydrocannabinol on spasticity related to chronic pain with
inconclusive results [107]. The other study focused on
the impact of dronabinol on neuropathic pain yielding
negative findings with limited validity regarding its preci-
sion in terms of statistical conclusiveness (n=7) [108].
Nevertheless, experts and affected patients repeatedly
describe positive effects of cannabinoids as compassion-
ate use for musculoskeletal nociceptive pain in the wake
of deteriorating spasticity. Among affected individuals,
neuropathic pain is occasionally reported to respond to
the administration of cannabinoids as well. Based on
insufficient evidence combined with unfavorable side
effects (e.g. constipation, drowsiness, xerostomia), the
administration of cannabinoids cannot be suggested for
the therapy of SCI-related pain.
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Non-pharmacological measures for
treatment of SCI-related pain
RECOMMENDATION 8: PHYSICAL ACTIVITY, EXERCISE
AND PHYSIOTHERAPEUTIC MEASURES
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↑↑
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↑
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
A recent meta-analysis suggests that physical activity has
a mild to moderate beneficial effect on chronic musculo-
skeletal pain related to SCI and emphasizes its favorable
benefit-risk profile [109]. Exemplarily, mild physical
activity (stretching and suchlike) performed two times a
week for the period of threemonths could positively influ-
ence nociceptive pain after SCI [110]. As another ex-
ample, SCI-related shoulder pain could likewise be
ameliorated by means of a specific therapeutic concept,
comprising an hour-long instructional course about a
specific personalized training or an eight-week tailored
training program for implementation at home, including
daily stretching and strengthening exercises by use of
elastic resistance bands every other day [111], [112],
[113]. From further cross-sectional studies it can also be
assumed that physiotherapeutic interventions could in
general have a positive influence on chronic pain [114],
[115].
Even though well-designed RCT on this topic are still
lacking [116], [117], [118], [119], physical activity and/or
physiotherapeutic measures are recommended to treat
SCI-related nociceptive pain. Based on the assumed
positive impact of physical activity and physiotherapy on
chronic pain in general, respectivemeasures are sugges-
ted for non-pharmacological neuropathic pain treatment.
RECOMMENDATION 9: PSYCHOTHERAPEUTIC TECH-
NIQUES
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Psychotherapeutic interventions have not been exten-
sively evaluated with respect to their efficacy in SCI-
related pain [116], [120]. In reference to the concept of
a multimodal therapeutic approach, both psychothera-
peutic and psychoeducational strategies may however
serve as a basis to raise awareness and help to better
understand underlying causes and causalities regarding
pain development, coping processes and corresponding
pain behavior. Among common psychotherapeutic
strategies, imaginative and hypnotherapeutic interven-
tions appear to be encouraging [121]. The cognitive be-
havior therapy also proved to have some effect in com-
bination with a pharmacological therapy concept in SCI
[122], [123]. Its fundamental assumption is based on
the idea that both pain behavior and cognitive appraisal
do have a crucial impact on perception and experience
of pain and might also be responsive to therapeutic ap-
proaches [124]. Further examples for promising psycho-
therapeutic approaches, which are yet lacking evidence
in the field of SCI, are the positive psychotherapy, the
mindfulness training, and the acceptance and commit-
ment therapy (ACT) [125], [126], [127], [128], [129].
Also, relaxation techniques are already a key element in
psychological treatment of chronic pain in general.
RECOMMENDATION 10: TRANSCRANIAL DIRECT-CUR-
RENT STIMULATION
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Transcranial direct-current stimulation (tDCS) is capable
of reducing neuropathic pain in SCI [130], [131], [132],
[133]. A recent meta-analysis [116] indeed confirmed
these findings on the basis of two RCTs [131], [132],
which had a sufficient methodological quality. tDCS is
well-tolerated, with instantly emerging mild headache of
limited duration as the only described side effect of rele-
vance. Notwithstanding the existing evidence, tDCS may
only be considered as current third-line therapy. This is
primarily explained by the availability of at least equally
effective pharmacological treatment options, which are
not only clinically well-established, but also well-tolerated.
Furthermore, tDCS is not widely available, and experience
in clinical routine is consequently meagre.
RECOMMENDATION11: TRANSCUTANEOUSELECTRICAL
NERVE STIMULATION
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
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INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
The therapeutic value of transcutaneous electrical nerve
stimulation (TENS) in therapy of pain after SCI is still being
discussed. Even though certain positive effects on
neuropathic pain were reported, the conclusiveness
based on one RCT (n=33) [134], one prospective con-
trolled trial (n=24) [135], and one case series (n=31)
[136] is limited due to substantial methodological short-
comings [116]. Moreover, investigations on possible long-
term effects are completely missing. Undesirable side
effects seem to be mild, but still are described to com-
prise a potential deterioration of spasticity and pain
symptoms as well.
With regard to nociceptive pain, two clinical studies sug-
gest a modulation of spasticity by application of TENS in
SCI [137], [138]. However, results regarding the impact
of TENS on nociceptive pain in other underlying diseases
are very heterogenous [139], [140], [141], [142]. Thus,
the application of TENSmay be considered for treatment
of neuropathic pain and nociceptive pain on a case-by-
case basis, if alternative treatment options are not
available.
RECOMMENDATION 12: ACUPUNCTURE
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Acupuncture is being discussed to have a therapeutic
value for both nociceptive pain and neuropathic pain.
This is based on two RCTs and one prospective controlled
trial for nociceptive pain [143], [144], [145], as well as
on one RCT [146] and one retrospective study with pre-
post comparison [147] for neuropathic pain. However,
sham-acupuncture has been shown to be equally effective
in nociceptive pain [147], [148]. In the light of lacking
superiority over a sham-treatment and also due to
methodological weaknesses, the application of acupunc-
ture may be waived in SCI-related pain [116].
RECOMMENDATION 13: MASSAGE, HEAT THERAPY AND
OSTEOPATHY
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
There is no convincing evidence proving efficacy of mas-
sage, heat therapy or osteopathy in SCI-related pain due
to methodological weaknesses, such as differentiation
of pain types, no randomization and small sample sizes
or single-blinding. Positive effects on SCI-related pain are
discussed and the need of accurately designed RCT is
being emphasized [63], [115], [145], [149], [150]. Con-
sidering both, positive experiences in other chronic pain
conditions and the good tolerability of these measures,
their application may be considered for pain after SCI.
RECOMMENDATION 14: HYDROTHERAPY
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Secondary literature frequently describes positive effects
of hydrotherapy on pain and psyche. The microgravity in
water is assumed to be crucial for reducing the com-
plained pain symptoms. Thismight be achieved by decom-
pression of body regions that are vulnerable to pressure
sores or of bones that are characterized by protuber-
ances, but also by the facilitation to voluntarily/actively
move paretic limbs in the water. Usual water tempera-
tures of 32°C/89.5°F might additionally alleviate spas-
ticity and also nociceptive pain as a secondary con-
sequence [151]. Accordingly, hydrotherapy may be useful
to treat nociceptive pain, but not neuropathic pain.
RECOMMENDATION 15: VISUAL ILLUSION AND MOTOR
IMAGERY
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Visual illusion techniques to treat neuropathic pain in SCI
have been shown to provide general pain relief in one
RCT without a relevant carry-over effect [132]. Two pre-
post comparison studies yielded controversial results
[152], [153], which does not allow to draw any firm con-
clusions.
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RECOMMENDATION 16: TRANSCRANIAL MAGNETIC
STIMULATION
INDICATION FOR THE TREATMENT OF NOCICEPTIVE PAIN
Degree of recommendation and related specifics: n/a
Strength of consent: n/a
INDICATION FOR THE TREATMENTOFNEUROPATHIC PAIN
Degree of recommendation and related specifics: ↔
Strength of consent: strong
BASIC INFORMATION AND BODY OF EVIDENCE
Based on a recent Cochrane study, transcranial magnetic
stimulation (TMS) cannot be recommended for the use
in central neuropathic pain (below-level) [116]. This meta-
analysis investigating non-pharmacological interventions
for chronic pain in people with spinal cord injury solely
considered one single-blinded randomized crossover
study with respect to TMS (n=13), which delivered nega-
tive results [154]. Only one single RCT (n=12) discusses
a significant positive effect of TMS on central neuropathic
pain relief, still lacking superiority with regard to the sham-
stimulation [155]. Due to methodological weaknesses,
this study was not considered for the aforementioned
meta-analysis. According to the literature available, the
data situation regarding TMS is unclear.
RECOMMENDATION 17: THERAPIES WITH ADVERSE
RISK-BENEFIT RATIO AND/OR OBSOLESCENCE
BASIC INFORMATION AND BODY OF EVIDENCE
Epidural spinal cord stimulation, deep brain stimulation,
motor cortex stimulation, selective rhizotomy including
dorsal root entry zone lesioning and myelotomy cannot
be recommended for treatment of pain related to SCI.
This is based on an insufficient level of evidence and
missing RCTs in combination with an adverse risk-benefit
ratio, especially when considering the invasiveness of the
mentionedmeasures. Nevertheless, selected reasonable
indications might not be ruled out on a case-by-case
basis.
Discussion
This clinical practice guideline was developed to provide
a structured and solid basis for clinical assessment and
reliable source for therapy of pain related to SCI in
German-speaking countries. Even though this guideline
is consensus-based and not developed by means of a
systematic review of existing evidence, the guideline
panel made every effort to meet the required terms for
achieving an appropriate and rigorous evaluation of rel-
evant literature as comprehensive and accurate as pos-
sible. Thus, the primary criterion for rating each of the
proposed recommendations was the appraisal of identi-
fied evidence and existing literature, respectively. How-
ever, in case of conflicting considerations, for instance
among members of the guideline panel, the final grade
of recommendation could potentially differ from those
that would be expected according to Table 2 and Table 3 .
In this respect, influencing factors were aspects concern-
ing practicability and suitability of therapeutic approaches
and interventions in clinical routine, ethical and economic
considerations, as well as the appreciation of risk-benefit
ratios, especially with regard to potential side effects.
Such considerations were then stated in the background
text of the respective recommendation.
Classification and diagnosis
With respect to the taxonomy of pain related to SCI, the
ISCIP classification is recommended (see statement 1.1)
since it is widely accepted and clearly specifies the differ-
ent pain types in relation to SCI [28], [156]. For example,
the distinction between at- and below-level neuropathic
pain is of particular importance, since it is a unique
characteristic of pain in SCI and considered to be caused
by different underlying mechanisms. While below-level
neuropathic pain (more than three levels below the NLI)
presents as central neuropathic pain caused by a spinal
cord lesion, at-level neuropathic pain (within three levels
relating to the NLI) is frequently due to lesions of both
nerve roots/peripheral nerves and spinal cord lesions,
potentially resulting in a mixed pain presentation with
peripheral and central neuropathic pain [12], [13].
From a clinical point of view, the distinction between
neuropathic pain and nociceptive pain is particularly
challenging at the level of injury, and, in case of sensory
incomplete lesions, also below-level. This is due to the
fact that perceived pain in these regions, irrespective of
its (sub-)type, formally meets one of the diagnostic criteria
for neuropathic pain, which is the presence of pain in
areas of abnormal sensory function [10], [11]. When using
the recommended ISCIPD (see statement 2.1), the dis-
tinction of both neuropathic pain and nociceptive pain
requires caution in these zones.
Pain is a frequent complication directly or indirectly
caused by SCI-related impairments of motor and sensory
function. Common causes aremuscular atrophy and also
immobilization in bed, e.g. due to pressure sores. Changes
with regard to biomechanics, a possibly inadequate sitting
position in the wheelchair (see also statement 6.8), non-
physiological gait patterns or transfer techniques are
further examples that need to be considered and ad-
dressed when evaluating pain as a (secondary) compli-
cation of SCI (see also statement 3.1) [157]. Occasionally,
such pain sources could also trigger other pain types or
vice versa and finally result in a worsening of other com-
plications in SCI (e.g. spasticity) [12], [93].
Clinical examination
The clinical examination of a patient with nociceptive pain
(musculoskeletal/visceral/other nociceptive pain) (see
statements 3.1 and 6.4) needs to include the inspection,
palpation, functional testing, evaluation of spasticity,
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contractures, myosclerosis, and the assessment of myo-
fascial trigger points, but should also comprise a critical
evaluation of symptoms relating to digestion, bowel and
bladder management.
If evaluating peripheral and central neuropathic pain in
SCI (see statement 3.2), a precise neurological exam-
ination is highly relevant (e.g. assessment of evoked
versus spontaneous pain). In this respect, competing
causes of aforementioned neuropathic pain characteris-
tics (e.g. allodynia in fibromyalgia) ought to be kept in
mind as well [158], [159], [160]. Even in complete SCI
according to the International Standards for Neurological
Classification of Spinal Cord Injury (ISNCSCI) [29], below-
level neuropathic pain can occur. This is most likely due
to the fact that a clinically complete SCI (ASIA Impairment
Scale A) does not necessarily imply a complete transec-
tion of all efferent and afferent nerve fibers within the
spinal cord. This occurrence could be reflected by the so-
called “zones of partial preservation (ZPP)” in ISNCSCI
and is frequently referred to as a “dyscomplete” lesion
[161], [162]. In case neuropathic pain is emerging within
the chronic phase of SCI, the examiner ought to consider
secondary complications of SCI as causative (e.g. syrin-
gomyelia or carpal tunnel syndrome) [12].
Supplemental questionnaires and scales can be used to
screen for neuropathic pain or to create a standardized
and systematic basis for follow-up examinations and to
evaluate the success of a previously initiated therapy
(e.g. the numeric rating scale (NRS), the visual analogue
scale (VAS), and the Likert-scale) (see statement 3.3). As
opposed to the douleur neuropathique 4 questions (DN4),
the spinal cord injury pain instrument (SCIPI), which was
specifically developed for screening of SCI-related
neuropathic pain, has recently been validated in German
and is publicly available [163].
Not only somatic, but also psychological factors could
influence the emergence and maintenance of pain (see
statements 2.2 and 2.3). Hence, chronic pain could con-
tribute to psychological stress and even trigger psycho-
reactive disorders (e.g. adaptive disorder or anxiety dis-
order). But strain ormental disorders could also enhance
the perception of chronic pain in individuals with SCI [57].
All these mentioned challenges in terms of the clinical
evaluation of nociceptive pain and neuropathic pain, in
combination with possible psychological influences in-
crease the probability of diagnostic uncertainty. If so, a
multidisciplinary approach, assisted by physical thera-
pists, occupational therapists, psychologists, but also
relevant medical specialists, such as neurologists, psy-
chiatrists, urologists, physiatrists, orthopedic surgeons,
and specialists for internal medicine should be chosen.
Medical diagnostics
Besides imaging (see statement 4.1), there are still other
selected laboratory tests available to evaluate nociceptive
pain. Most of those are at least partially controversial
with respect to their psychometric properties. These tests
comprise the ultrasonography ofmyofascial trigger points,
the analysis of heart rate variability, as well as thermo-
graphy for assessing the impact of the autonomic nervous
system on the pain occurrence [164]. Instrumented gait
and movement analysis, along with functional elec-
tromyography might additionally help to justify further
targeted diagnostics and/or physical interventions, includ-
ing the indication of medical aids. Finally, instrumented
muscle function testing could provide information on
aspects like the maximal strength, endurance, and fa-
tigability. This again might give early hints on possibly
emerging secondary complications (see also recommen-
dation 8). However, such approaches still lack dissemina-
tion and expertise among SCI centers.
For more detailed neuropathic pain evaluation, parts of
the QST (see statement 4.3) might also be helpful in de-
tecting neuropathic pain in the early phase of SCI (see
statement 5.3) [54].
Prediction and prevention of pain in SCI
To effectively reduce the likeliness of chronic disease
course for nociceptive pain (see statement 5.2), all in-
volved therapists and also medical specialists are re-
quired to counteract muscular atrophies, tendon contrac-
tions and weakening of muscles with preserved voluntary
function as early as possible. If some loss of function has
already occurred, e.g. due to long-term immobilization, it
is important to encourage and support the patients in
terms of cautiously returning towards the pre-existing
activities of daily living, still aiming at the best recovery
possible, however without creating other complications.
For example, extensive mobilization bears the risk of
overstraining connective tissue,muscles and joints, which
can elicit musculoskeletal nociceptive pain.
With regard to neuropathic pain and according to state-
ment 5.3 it seems appropriate to continuously monitor
acutely injured patients with signs of allodynia, which
might allow for a timely and effective treatment of
neuropathic pain and potentially diminish the likeliness
of a chronic disease course.
Expectations on treatment and
associated considerations
To meet the content of statement 6.1, aims of an inten-
ded therapy should mostly be developed based on an
interdisciplinary approach and patient-centered consider-
ations. In most cases, a partial pain relief appears to be
a rational endeavor. Patients under treatment should
continuously be supervised to ensure both their compli-
ance and the therapeutic success. Given the frequent
recurrence and the chronic disease course as a con-
sequence of SCI, practitioners should take care of a
comprehensive and accurate documentation of all
emerging pain aspects and causalities (e.g. ICD-10
codes), to guarantee an adequate and sufficient supply
of medication, as well as any other means/therapies to
treat SCI-related pain (see statement 6.3), and to avoid
recourse claims from health insurance funds.
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Once the decision was taken to additionally address
emerged nociceptive pain symptoms with adjuvants ac-
cording to the WHO pain ladder, potential synergistic ef-
fects on both nociceptive pain and neuropathic pain
should be considered (see statements 6.5 and 6.10). In
contrast, adverse effects and relevant interactions of
certain pharmacological agents, as well as moderate ef-
fect sizes should also play a role in therapeutic delibera-
tions (see statements 6.6 and 6.11). For example, the
administration of opioids could severely deteriorate
neurogenic bowel dysfunction and lacks sufficient evi-
dence for treatment of myofascial pain (see statement 7
and recommendations 3.1 and 3.2). Potential restrictions
regarding drug approval need to be considered (e.g. no
approval for long-term administration of metamizole in
Germany) (see statements 6.5, 6.7 and 6.11). In case of
an off-label use of pharmacological and non-pharmacolo-
gical therapeutics, patients need to be informed appropri-
ately.
Besides pharmacotherapy, the supply with appropriate
assistive devices is highly relevant in the context of
identifying potential pain causalities (see statement 6.8).
One of the most critical aspects is the accuracy of
wheelchair fitting, which has to be re-evaluated on a
regular basis over the years. Particularly in the acute
phase, the appropriate wheelchair should not be finally
adapted until the final stage of neurological and functional
recovery following acute SCI has been reached.
Pharmacological options for treatment
of SCI-related pain
As already indicated by statement 6.2, SCI-specific evi-
dence in terms of pain therapy is based on only a rela-
tively small number of valuable, valid, and reliable clinical
trials summarized in five meta-analyses [19], [20], [21],
[22], [23]. In case of pharmacological treatment, such
evidence is largely limited to the application of anticon-
vulsants and antidepressants (see recommendations 1.1
through 2.3). Thus, therapeutic approaches in clinical
routine are frequently related to own subjective clinical
experiences or experiences from other underlying dis-
eases. This clinical practice guideline was dedicated to
consequently providing a comprehensive guidance for a
reproducible management of pain in a standardized
manner, even if relevant evidence is vague or missing.
In case this clinical practice guideline is not sufficient yet
to address certain pain presentations in a given case,
the therapeutic strategy could still be oriented towards
the general recommendations for treatment of pain [165],
[166]. The CPGs for diagnostics and treatment of chronic
neuropathic pain [100], as well as the CPG about the
long-term administration of opioids in non-malignant pain
[167] are also of relevance in this context. Respecting
the increasingly ageing patient population that is suffering
from SCI [168], the PRISCUS list, specifying inappropriate
medications in elderly [169], should also be considered.
Concerning the pharmacological therapy in general and
with regard to the treatment of multimorbid elderly pa-
tients in particular, the therapeutic concept should always
be based on a reasoned strategy. This includes a careful
risk-benefit analysis regarding the expected effect size
in relation to possible side effects. In case of polyphar-
macy, potential adverse interactions between different
agents ought to be kept in mind. Furthermore, several
drugs noted and recommended above can have a specific
impact on spinal cord injured individuals, e.g. deteriora-
tion of an existing neurogenic bowel and bladder dysfunc-
tion or an increasing respiratory impairment in case of
cervical injuries (Table 8).
Non-pharmacological measures for
treatment of SCI-related pain
As compared to pharmacological treatments for SCI-
related pain, the situation in terms of relevant literature
is even worse in reference to non-pharmacological
measures. Thesemeasures commonly represent comple-
mentary tools in SCI pain management. For instance,
such approaches should seriously be considered in the
case of prevailing nociceptive pain, which frequently
results from disorders of the musculoskeletal/locomotor
system. Among the non-pharmacological therapy ap-
proaches, “physical activity, exercise and physiotherapeu-
tic measures” are the only ones that received an “ought
to” and “should” recommendation in this CPG, each de-
pending on the specific pain type (see recommenda-
tion 8). Despite the fact of only few existing evidences,
this was mainly justified by two reasons:
1. according to the literature available, the beneficial
impact of these measures on chronic pain is not am-
biguous when applied properly, and
2. long-term clinical experience, entailing a broad and
favorable acceptance for suchmeasures in both pain
medicine and the field of SCI. For achieving a suffi-
cient application of those measures in terms of an
effective complementary therapy, it mightmake sense
to evaluate regional sports rehabilitation programs
suitable for respective SCI conditions.
Given the huge clinical relevance of pain in general and
musculoskeletal nociceptive pain in particular, spinal
cord injury centers and even associated rehabilitation
clinics might consider to take up the issue of pain man-
agement in separate and specialized training programs
for their healthcare professionals. Such programs would
enable the facilities to impart knowledge about the benign
character, but also the pain-associated dangers and
challenges of structural degenerations, which againmight
lead to a successive loss of function, activity, and finally
participation.
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Table 9: Recommendations for selected substances and measures in the therapy of SCI-related neuropathic pain
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Figure 2: Clinical algorithm for assessment and management of individuals with pain after spinal cord injury
Summary of pharmacological and
non-pharmacological treatments for
neuropathic pain
As illustrated by the results of the consensus building for
this CPG, effective and lasting treatment options for
neuropathic pain are limited. Table 9 summarizes the
given agents and complementary measures for treat-
ment of SCI-related neuropathic pain, arranged according
to the degree of recommendation and divided into
first- through to fourth-line therapies, as well as therapies
that cannot be recommended.
Conclusion
In summary, the overall evidence in respect to SCI-related
pain is still sparse, which underlines the necessity for
accurately designed RCTs investigating pharmacological
and non-pharmacological treatment strategies. Mean-
while, a strictly developed clinical practice guideline may
support two highly relevant endeavors:
1. It represents a clinical guidance for healthcare profes-
sionals in daily routine. This is illustrated by the clinical
pathway in Figure 2, which is fundamentally based
on a multimodal therapeutic approach.
2. It may serve as basis towards a gradual and ongoing
improvement of painmanagement in SCI, as it reveals
the most crucial gaps of evidence that ought to be
primarily addressed in conceivable future trials.
Notes
Original (German) version
This guideline is also available for free download in Ger-
man language on the AWMF website (register number
179/006): https://www.awmf.org/uploads/tx_szleitlinien/
179-006l_S2k_Schmerzen_Querschnittlaehmung_
2018-08.pdf.
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